–Eyes on the FDA approval of fruquintinib in Nov
–Solid 2Q23 earnings quality; Eyes on upmarket
Positive profit alert for FY22; eyeing for a good FY23E
Weather short-term headwinds in 2Q24; eyes on 2H24E recovery
1H24E preview: eyes on Android recovery and smart tech growth
Labor Market Gender Gaps in Türkiye: A Bird’s Eye View
C-MER Eye Care (3309 HK) 疫情带来更多并购机会
Eyeing on the pace of fundamental recovery post sentiment rebound
–Eye on GAP revitalization & livestreaming ecommerce expansion
Eyes on the recovery and risk-reward